Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 20, 2025
Reporting Period: Event-based report regarding the termination of clinical trials and settlement of a material agreement.
Key Financial Metrics and Obligations
This filing does not report standard periodic financial metrics such as revenue, profit, or cash flow. It discloses specific liabilities and settlement costs:
- Settlement Payment: $300,000 partial payment to Theradex Systems, Inc. to settle outstanding liabilities of approximately $557,000.
- Remaining Liabilities: Approximately $750,000 owed under five separate research site agreements with various hospitals.
- Anticipated Winddown Costs: Additional expenses expected for trial closeout activities, with the vast majority to be recorded in the fourth quarter of 2025. Specific amounts are currently being assessed.
Material Changes and Events
The filing details the following material changes:
- Termination of Master Agreement: Following a termination notice from Theradex Systems, Inc. on October 15, 2025, the Company entered into a Release and Settlement Agreement on November 20, 2025.
- Cessation of Clinical Trials: The Company committed to a plan to discontinue clinical trials for Ropidoxuridine. Enrollment will end immediately, and winddown activities will commence to comply with FDA requirements.
- Debt Resolution: The $300,000 payment resolves all claims relating to the $557,000 debt previously owed to Theradex.
Outlook, Risks, and Management Commentary
Management Commentary: The Company expects to incur additional expenses related to trial closeout activities. These costs are subject to assumptions and actual results may materially differ. The Company may also incur other costs not currently contemplated.
Risks and Contingencies:
- Forward-looking statements regarding winddown costs are subject to risks and uncertainties.
- Success in winding down the Clinical Trials in compliance with FDA requirements is not guaranteed.
- The Company does not undertake an obligation to update forward-looking statements publicly.
Key Facts for Investor Verification
- Verify the exact timing and amount of the $300,000 settlement payment to Theradex.
- Confirm the status of the remaining $750,000 in obligations to research sites and the payment schedule.
- Monitor the fourth quarter 2025 financial statements for the final recorded winddown costs, which are currently estimated but not finalized.
- Review the impact of the discontinued Ropidoxuridine trials on the Company's future pipeline and cash burn rate.